Concomitant use of immunomodulators and dosage are important variables in the development of antidrug antibodies (ADAs) for patients receiving infliximab for Crohn disease, investigators report.
Using data from a study (N = 220) of the infliximab biosimilar CT-P13 in patients with Crohn disease, investigators said they have improved understanding of the clearance of infliximab and its predictive value for the development of antidrug antibodies (ADA).
Investigators found that initial infliximab clearance, concomitant use of immunomodulators, and infliximab dosage were statistically significant predictors of the time to development of ADAs.
Investigators reported that the risk for ADA increases 61% for every increase of 0.1 L/day in drug clearance; however, it decreases by 41% if immunomodulators are administered concomitantly, and it also decreases 29% with every increase in dosage of 100 mg.
They calculated that for a patient with infliximab clearance of 0.2 L/day who is not taking immunomodulators and has an infliximab dose of 328 mg, the average time to first ADA would be 374 days.
With higher clearance of 0.4 L/day, also with dosage of 328 mg and no immunomodulators, the ADA onset would occur in 144.5 days.
A higher starting infliximab dose of 428 mg would lengthen the time to onset to 203 days, and adding immunomodulator treatment would extend time to ADA onset to 354 days, they said.
“Our results suggest that early assessment of clearance should guide treatment optimization with infliximab in patients with Crohn disease, including the addition of concomitant immunosuppressants or increasing the dose during induction,” authors of the study concluded.
Reference
Kutschera M, Primas C, Reinish S, et al. Initial clearance of infliximab is a predictor for the time of formation of anti-drug antibodies. Presented at: ECCO’21 Congress; July 2-3 and 8-10, 2021. Poster DOP74
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
BioRationality: How Developers Can Expand Their Monoclonal Antibody Biosimilar Portfolio
March 24th 2025Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and technological feasibility, whereas other biologics encounter development challenges but may see increased adoption as regulatory frameworks advance.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Promising Results for Ustekinumab, Adalimumab Biosimilars Presented at AAD
March 18th 2025Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved interchangeable with reference adalimumab, according to posters at the American Academy of Dermatology (AAD) annual meeting.